HGH Stock Overview
Heartland Group Holdings Limited provides various financial services in New Zealand and Australia.
Heartland Group Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$1.63|
|52 Week High||NZ$2.59|
|52 Week Low||NZ$1.62|
|1 Month Change||-9.95%|
|3 Month Change||-14.66%|
|1 Year Change||-29.74%|
|3 Year Change||2.52%|
|5 Year Change||-8.43%|
|Change since IPO||89.54%|
Recent News & Updates
Should You Be Adding Heartland Group Holdings (NZSE:HGH) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
|HGH||NZ Banks||NZ Market|
Return vs Industry: HGH underperformed the NZ Banks industry which returned -11.5% over the past year.
Return vs Market: HGH underperformed the NZ Market which returned -19.1% over the past year.
|HGH Average Weekly Movement||4.7%|
|Banks Industry Average Movement||3.6%|
|Market Average Movement||3.9%|
|10% most volatile stocks in NZ Market||7.7%|
|10% least volatile stocks in NZ Market||2.8%|
Stable Share Price: HGH is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: HGH's weekly volatility (5%) has been stable over the past year.
About the Company
Heartland Group Holdings Limited provides various financial services in New Zealand and Australia. The company offers savings accounts, term deposits, and direct and business call accounts. It also provides home loans, business loans, term loans, revolving credit, car loans, and reverse mortgage lending and other financial services.
Heartland Group Holdings Fundamentals Summary
|HGH fundamental statistics|
Is HGH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HGH income statement (TTM)|
|Cost of Revenue||NZ$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.13|
|Net Profit Margin||37.48%|
How did HGH perform over the long term?See historical performance and comparison
6.7%Current Dividend Yield
Is HGH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HGH?
Other financial metrics that can be useful for relative valuation.
|What is HGH's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does HGH's PE Ratio compare to its peers?
|HGH PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
BJTM Bank Pembangunan Daerah Jawa Timur
ALR Alior Bank
RCB Rizal Commercial Banking
HGH Heartland Group Holdings
Price-To-Earnings vs Peers: HGH is expensive based on its Price-To-Earnings Ratio (12.1x) compared to the peer average (7.4x).
Price to Earnings Ratio vs Industry
How does HGH's PE Ratio compare vs other companies in the Global Banks Industry?
Price-To-Earnings vs Industry: HGH is expensive based on its Price-To-Earnings Ratio (12.1x) compared to the Global Banks industry average (8.9x)
Price to Earnings Ratio vs Fair Ratio
What is HGH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||12.1x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HGH's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of HGH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HGH (NZ$1.63) is trading below our estimate of fair value (NZ$2.64)
Significantly Below Fair Value: HGH is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Heartland Group Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HGH's forecast earnings growth (8.5% per year) is above the savings rate (2.1%).
Earnings vs Market: HGH's earnings (8.5% per year) are forecast to grow faster than the NZ market (6% per year).
High Growth Earnings: HGH's earnings are forecast to grow, but not significantly.
Revenue vs Market: HGH's revenue (7.6% per year) is forecast to grow faster than the NZ market (5.6% per year).
High Growth Revenue: HGH's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HGH's Return on Equity is forecast to be low in 3 years time (11.4%).
Discover growth companies
How has Heartland Group Holdings performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HGH has a high level of non-cash earnings.
Growing Profit Margin: HGH's current net profit margins (37.5%) are higher than last year (36.8%).
Past Earnings Growth Analysis
Earnings Trend: HGH's earnings have grown by 8.3% per year over the past 5 years.
Accelerating Growth: HGH's earnings growth over the past year (9.3%) exceeds its 5-year average (8.3% per year).
Earnings vs Industry: HGH earnings growth over the past year (9.3%) exceeded the Banks industry 1.2%.
Return on Equity
High ROE: HGH's Return on Equity (11.8%) is considered low.
Discover strong past performing companies
How is Heartland Group Holdings's financial position? (This company is analysed differently as a bank or financial institution)
Financial Health Score3/6
Financial Health Score 3/6
Allowance for Bad Loans
Low Risk Liabilities
Low Risk Deposits
Level of Bad Loans
Financial Position Analysis
Debt to Equity History and Analysis
Financial Institutions Analysis
Asset Level: HGH's Assets to Equity ratio (8.8x) is low.
Allowance for Bad Loans: HGH has a low allowance for bad loans (38%).
Low Risk Liabilities: 57% of HGH's liabilities are made up of primarily low risk sources of funding.
Loan Level: HGH has an appropriate level of Loans to Assets ratio (87%).
Low Risk Deposits: HGH's Loans to Deposits ratio (171%) is high.
Level of Bad Loans: HGH has a high level of bad loans (2.2%).
Discover healthy companies
What is Heartland Group Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
|Heartland Group Holdings Dividend Yield vs Market|
|Company (Heartland Group Holdings)||6.7%|
|Market Bottom 25% (NZ)||2.8%|
|Market Top 25% (NZ)||6.3%|
|Industry Average (Banks)||5.1%|
|Analyst forecast in 3 Years (Heartland Group Holdings)||7.9%|
Notable Dividend: HGH's dividend (6.75%) is higher than the bottom 25% of dividend payers in the NZ market (2.85%).
High Dividend: HGH's dividend (6.75%) is in the top 25% of dividend payers in the NZ market (6.28%)
Stability and Growth of Payments
Stable Dividend: HGH's dividend payments have been volatile in the past 10 years.
Growing Dividend: HGH's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (68.2%), HGH's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: HGH's dividends in 3 years are forecast to be covered by earnings (76.6% payout ratio).
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Jeffrey Kenneth Greenslade, also known as Jeff, LLB, serves as Chief Executive Officer of Heartland Group Holdings Ltd. He serves as Non-Independent Non-Executive Director of Heartland Bank Limited and...
CEO Compensation Analysis
|Jeff Greenslade's Compensation vs Heartland Group Holdings Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||n/a||n/a|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||n/a||n/a|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||NZ$2m||NZ$900k|
Compensation vs Market: Insufficient data to establish whether Jeff's total compensation is reasonable compared to companies of similar size in the NZ market.
Compensation vs Earnings: Insufficient data to compare Jeff's compensation with company performance.
Experienced Management: HGH's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Experienced Board: HGH's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|24 Mar 22||SellNZ$91,455||Laura Byrne||Individual||40,000||NZ$2.29|
|15 Dec 21||SellNZ$94,600||Laura Byrne||Individual||40,000||NZ$2.36|
|Owner Type||Number of Shares||Ownership Percentage|
|Company Controlled Foundation||6,475,976||0.9%|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.6%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Heartland Group Holdings Limited's employee growth, exchange listings and data sources
- Name: Heartland Group Holdings Limited
- Ticker: HGH
- Exchange: NZSE
- Founded: 1875
- Industry: Diversified Banks
- Sector: Banks
- Implied Market Cap: NZ$1.143b
- Shares outstanding: 705.32m
- Website: https://shareholders.heartland.co.nz
Number of Employees
- Heartland Group Holdings Limited
- Heartland House
- Level 3
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HGH||NZSE (New Zealand Stock Exchange)||Yes||New Ordinary Shares||NZ||NZD||Feb 2011|
|HGH||ASX (Australian Securities Exchange)||Yes||New Ordinary Shares||AU||AUD||Feb 2011|
|HGH||CHIA (Chi-X Australia)||Yes||New Ordinary Shares||AU||AUD||Feb 2011|
|73X||BST (Boerse-Stuttgart)||Yes||New Ordinary Shares||DE||EUR||Feb 2011|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/29 00:00|
|End of Day Share Price||2022/09/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.